Author
Listed:
- Jennifer J. Knox
(University Health Network)
- Gun Ho Jang
(Ontario Institute for Cancer Research)
- Robert C. Grant
(University Health Network
Ontario Institute for Cancer Research)
- Amy Zhang
(Ontario Institute for Cancer Research)
- Lucy Ma
(University Health Network)
- Elena Elimova
(University Health Network)
- Raymond Jang
(University Health Network)
- Malcolm Moore
(University Health Network)
- James Biagi
(Kingston Health Sciences Centre)
- Mustapha Tehfe
(Centre Hospitalier de l’Université de Montréal (CHUM))
- Ravi Ramjeesingh
(QEII Health Sciences Centre)
- Erica S. Tsang
(University Health Network)
- Spring Holter
(University Health Network)
- Stephanie Ramotar
(University Health Network)
- Shawn Hutchinson
(University Health Network)
- Sheng-Ben Liang
(University Health Network)
- Ilinca M. Lungu
(Ontario Institute for Cancer Research Toronto)
- Shari Moura
(University Health Network)
- Yifan Wang
(The Research Institute of the McGill University Health Centre
The Rosalind & Morris Goodman Cancer Institute)
- Sheron Perera
(University Health Network)
- Michelle Chan-Seng-Yue
(Ontario Institute for Cancer Research)
- Maryam Monajemzadeh
(University Health Network)
- Kyaw Aung
(The University of Texas at Austin)
- Rebecca Prince
(University Health Network)
- Joan Miguel Romero
(The Research Institute of the McGill University Health Centre
The Rosalind & Morris Goodman Cancer Institute)
- Jesus Fuentes-Antras
(University Health Network)
- Galileo A. Gonzalez Conchas
(University Health Network)
- Sarah Picardo
(University Health Network)
- Ricardo Gonzalez
(University Health Network)
- Sangeet Ghai
(University Health Network
University of Toronto)
- Korosh Khalili
(University Health Network
University of Toronto)
- Tae Kyoung Kim
(University Health Network
University of Toronto)
- Karen Ng
(Ontario Institute for Cancer Research)
- John Bartlett
(University Health Network
Western General Hospital)
- Trevor J. Pugh
(Ontario Institute for Cancer Research Toronto
Princess Margaret Cancer Centre University Health Network)
- Sangeetha N. Kalimuthu
(University Health Network
University Health Network)
- Sandra E. Fischer
(University Health Network
University Health Network)
- Julie M. Wilson
(Ontario Institute for Cancer Research)
- Anna Dodd
(University Health Network)
- George Zogopoulos
(The Research Institute of the McGill University Health Centre
The Rosalind & Morris Goodman Cancer Institute)
- Barbara T. Grünwald
(University Health Network
University Hospital Essen
West German Cancer Center)
- Faiyaz Notta
(University Health Network
Ontario Institute for Cancer Research)
- Steven Gallinger
(University Health Network
Ontario Institute for Cancer Research)
- Grainne M. O’Kane
(University Health Network
University College Dublin)
Abstract
Integrated whole genome and transcriptome sequencing can unveil distinct molecular subgroups in pancreatic cancer (PDAC). The COMPASS trial (NCT02750657) enrolled 268 patients with advanced PDAC; patients were given either modified (m) FOLFIRINOX or Gemcitabine-nab-paclitaxel (GnP) as per physicians choice. Median follow-up is 52 months and median overall survival in those receiving mFOLFIRINOX is 10.6 months and 8.4 months for GnP. KRAS specific mutants and allelic states alone are not prognostic; however basal-like PDAC are more likely to harbour major imbalances in mutant KRAS (KRASmaj). In the presence of KRASmaj, pre-existing type II DM is more common. Distinct prognostic cohorts include homologous-recombination deficient PDAC, predictive of mFOLFIRINOX response. Basal-like PDAC and patients exhibiting evidence of systemic inflammation as annotated using the Gustave Roussy Immune Score are unique poor prognostic cohorts. The latter associates with low CD8 T cell infiltration while basal-like PDAC documents an inflamed tumour microenvironment.
Suggested Citation
Jennifer J. Knox & Gun Ho Jang & Robert C. Grant & Amy Zhang & Lucy Ma & Elena Elimova & Raymond Jang & Malcolm Moore & James Biagi & Mustapha Tehfe & Ravi Ramjeesingh & Erica S. Tsang & Spring Holter, 2025.
"Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial,"
Nature Communications, Nature, vol. 16(1), pages 1-14, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60808-z
DOI: 10.1038/s41467-025-60808-z
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60808-z. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.